T-0632

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532803

CAS#: 169042-78-8

Description: T-0632 is a novel potent and selective CCKA receptor antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

T-0632 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 532803
Name: T-0632
CAS#: 169042-78-8
Chemical Formula: C29H27FN2O5
Exact Mass: 502.1904
Molecular Weight: 502.54
Elemental Analysis: C, 69.31; H, 5.42; F, 3.78; N, 5.57; O, 15.92


Synonym: T-0632, T 0632, T0632

IUPAC/Chemical Name: 3-[(3S)-1-(2-fluorophenyl)-6-methoxy-2-oxo-3-(1,2,3,4-tetrahydronaphthalene-2-carbonylamino)indol-3-yl]propanoic acid

InChi Key: RORYEMYJJAIHBK-PRTIIRGTSA-N

InChi Code: InChI=1S/C29H27FN2O5/c1-37-21-12-13-22-25(17-21)32(24-9-5-4-8-23(24)30)28(36)29(22,15-14-26(33)34)31-27(35)20-11-10-18-6-2-3-7-19(18)16-20/h2-9,12-13,17,20H,10-11,14-16H2,1H3,(H,31,35)(H,33,34)/t20?,29-/m0/s1

SMILES Code: O=C(O)CC[C@@]1(NC(C2CC3=C(C=CC=C3)CC2)=O)C(N(C4=CC=CC=C4F)C5=C1C=CC(OC)=C5)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Tibaduiza EC, Chen C, Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem. 2001 Oct 12;276(41):37787-93. Epub 2001 Aug 9. PubMed PMID: 11498540.

2: Dong M, Vattelana AM, Lam PC, Orry AJ, Abagyan R, Christopoulos A, Sexton PM, Haines DR, Miller LJ. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding. Mol Pharmacol. 2015 Jan;87(1):130-40. doi: 10.1124/mol.114.095430. Epub 2014 Oct 15. PubMed PMID: 25319540; PubMed Central PMCID: PMC4279081.

3: Niederau C, Grendell JH. Role of cholecystokinin in the development and progression of acute pancreatitis and the potential of therapeutic application of cholecystokinin receptor antagonists. Digestion. 1999;60 Suppl 1:69-74. PubMed PMID: 10026436.

4: Taniguchi H, Yomota E, Kume E, Shikano T, Endo T, Nagasaki M. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol. 1997 Feb;73(2):105-12. PubMed PMID: 9074944.